Allurion restates Q1, posts GAAP profit from fair-value gains as revenue falls 33%

Snapshot - Allurion Technologies, Inc. (NYSE: ALUR)

Straight to the point: Allurion has restated its Q1 2024 results after discovering a material error tied to weaknesses in accounting controls. The company shows a small GAAP net income for Q1 2024 driven largely by non‑cash fair‑value gains on liabilities, but underlying operating performance weakened (revenue down, continued operating losses and cash burn). Management acknowledges material internal control weaknesses and a going‑concern uncertainty. Key financings (Revenue Interest Financing, PIPE, Fortress term loan, and a later RTW note purchase refinancing) complicate the capital structure and create recurring or contingent cash obligations.

Key facts and statistics (restated Q1 2024)
- Revenue: $9.386 million (Q1 2024) vs $14.071 million (Q1 2023) - down 33%
- Gross profit: $6.866 million (Q1 2024) - down 38% YoY
- Operating expenses (total): $18.256 million (Q1 2024) - operating loss $11.390 million
- Other income (expense), net: +$13.462 million driven by fair‑value changes (warrants, earn‑outs, RIF/PIPE) - swung result to GAAP net income
- Net income (restated): $1.996 million (Q1 2024) vs net loss $17.801 million (Q1 2023)
- EPS (basic / diluted): $1.04 / $0.96 (Q1 2024) - weighted avg shares basic 1,911,181
- Cash & cash equivalents: $29.682 million (balance sheet) - cash & restricted cash in cashflow $30.068 million
- Cash used in operating activities: $(8.636) million in Q1 2024
- Total assets: $59.988 million; Total liabilities: $126.150 million -> Stockholders' deficit $(66.162) million
- Accumulated deficit: $(213.013) million (restated)
- Significant liabilities (carrying/fair values at 3/31/2024): Fortress Term Loan principal $43.1M; Revenue Interest Financing liability $35.0M (FVO); Earn‑out liabilities $9.8M; Public warrant liabilities $3.329M; PIPE Conversion Option $7.51M
- Inventory: $5.631M; Accounts receivable, net: $16.159M
- Reverse stock split: 1‑for‑25 effective Jan 3, 2025 (financials retroactively adjusted)
- Restatement: Error discovered that misbooked OCI / fair‑value adjustments (no impact to revenue, gross profit, operating expenses, operating loss or cash & cash equivalents) - material weakness identified in internal controls due to insufficient public‑company accounting experience

Positive aspects of the income statement / position
- GAAP net income in Q1 2024 of $2.0M (restated) - reflects large non‑cash fair‑value gains (primarily earn‑out and warrant remeasurements). This produced positive headline earnings and raised EPS for the quarter.
- Management reduced sales & marketing and R&D spend year‑over‑year (Sales & Marketing down $5.7M; R&D down $2.1M), reflecting cost discipline and a strategic pullback in spending where revenues slowed.
- Cash balance (~$30M) provides near‑term runway but is limited given continuing cash burn (~$8.6M operating use in Q1).
- Subsequent financing activity (April 2024 Note Purchase Agreement) provided $48M to refinance Fortress Term Loan - shows access to capital partners (RTW) post quarter (but changes capital structure materially).

Negative aspects of the income statement / risks to watch
- Core sales weakness: Revenue down 33% YoY - fewer balloon unit orders and lower re‑orders by distributors; gross profit fell 38% and operating loss remains large at $11.4M.
- Net income is driven by volatile, non‑cash fair‑value movements (warrants, earn‑outs, derivatives). Those can reverse - underlying operating cash flows remain negative.
- Balance sheet stress: liabilities exceed assets by $66M; accumulated deficit $213M - the company discloses substantial doubt about its ability to continue as a going concern for one year from issuance of these statements.
- Structural recurring obligations: Revenue Interest Financing (original $40M) creates royalty‑style payments (historically up to 6-10% of net sales; amended to higher rates in 2024 - see subsequent amendment increasing royalty rates up to 12% under certain thresholds), plus contingent earn‑out shares and numerous warrants and convertible features that amplify dilution or cash outcomes.
- Material weaknesses in internal controls led to restatement; remediation underway (hiring accounting staff, ERP implementation, external advisors) - but the restatement undermines financial reporting reliability in the near term.
- High potential dilution: public warrants, rollover warrants, earn‑out shares (360,000 reserved), convertible instruments and equity facilities create meaningful dilution risk if converted/exercised.
- Cash burn remains a near‑term pressure; forecasts depend on additional financing, improved sales execution and ability to manage royalty and debt covenants.

What to watch next
- Revenue trends and distributor re‑order behavior (will sales stabilize or continue to decline?).
- Cash runway after Q1 and effects of the April 2024 note financing (how much runway, whether conversion limits or shareholder approvals impact dilution).
- Progress on remediation of internal control material weaknesses and any auditor commentary going forward.
- Royalty payments under the Revenue Interest Financing (timing & magnitude) and any required cash catch‑up payments if sales targets aren't met.
- Volatility in fair‑value line items (earn‑out, warrants, RIF/PIPE option) that swing GAAP earnings quarter‑to‑quarter.

Bottom line: Allurion is a product‑stage med‑device company with meaningful commercial traction in global markets but current operating performance is weak, balance sheet liabilities exceed assets, and GAAP profitability is driven by volatile non‑cash fair‑value adjustments rather than sustainable operating margins. Internal control issues and going‑concern language increase execution risk. Investors should prioritize cash runway, remediation progress, and concrete improvements in organic revenue before assuming the headline net income is durable.